Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients

HFCAS OpenIR

	Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients
其他题名	Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients
	2017
发表期刊	CHINESE JOURNAL OF CANCER RESEARCH
ISSN	1000-9604
摘要	Objective: To investigate potential prognostic factors affecting patient outcomes and to evaluate the optimal methods and effects of radiotherapy (RT) in the management of extramedullary plasmacytoma (EMP).
其他摘要	Objective: To investigate potential prognostic factors affecting patient outcomes and to evaluate the optimal methods and effects of radiotherapy(RT) in the management of extramedullary plasmacytoma(EMP). Methods: Data from 55 patients with EMP between November 1999 and August 2015 were collected. The median age was 51(range, 22-77) years. The median tumor size was 3.5(range, 1.0-15.0) cm. The median applied dose was 50.0(range, 30.0-70.0) Gy. Thirty-nine patients(70.9%) presented with disease in the head or neck region. Twelve patients received RT alone, 9 received surgery(S) alone, 3 received chemotherapy(CT) alone, and 3 patients did not receive any treatment. Combination therapies were applied in 28 patients. Results: The median follow-up duration was 56 months. The 5-year local recurrence-free survival(LRFS), multiple myeloma-free survival(MMFS), progression-free survival(PFS) and overall survival(OS) rates were 79.8%, 78.6%, 65.2% and 76.0%, respectively. Univariate analysis revealed that RT was a favourable factor for all examined endpoints. Furthermore, head and neck EMPs were associated with superior LRFS, MMFS and PFS. Tumor size <4 cm was associated with superior MMFS, PFS and OS; serum M protein negativity was associated with superior MMFS and PFS; age ≥50 years and local recurrence were associated with poor MMFS. The dose ≥45 Gy group exhibited superior 5-year LRFS, MMFS and PFS rates(94.7%, 94.4%, 90.0%, respectively), while the corresponding values for the dose <45 Gy group were 62.5%(P=0.008), 53.3%(P=0.036) and 41.7%(P<0.001). Conclusions: Involved-site RT of at least 45 Gy should be considered for EMP. Furthermore, patients with head and neck EMP, tumor size <4 cm, age <50 years and serum M protein negativity had better outcomes.
关键词	SOLITARY PLASMACYTOMA RADIATION-THERAPY CLINICAL-FEATURES ONCOLOGY-GROUP SOFT-TISSUE NECK HEAD BONE MULTICENTER GUIDELINES Extramedullary plasmacytoma prognostic factors radiotherapy multiple myeloma
收录类别	CSCD
语种	英语
CSCD记录号	CSCD:6101484
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/65046
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients[J]. CHINESE JOURNAL OF CANCER RESEARCH,2017,29.
APA	(2017).Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients.CHINESE JOURNAL OF CANCER RESEARCH,29.
MLA	"Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients".CHINESE JOURNAL OF CANCER RESEARCH 29(2017).